Overview
Comparison of a New Masterful Preparation to Kligman's Trio in the Treatment of Melasma
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2023-11-15
2023-11-15
Target enrollment:
0
0
Participant gender:
All
All
Summary
Kligman's trio remains the gold standard treatment for melasma. It contain hydroquinone which is an effective anti-melanogenic compound but that has poor tolerance and numerous side-effects. Thiamidol has been proven to be at least as effective as hydroquinone and has a very good safety profile. The objective of this study is to compare the Kligman's trio to the same preparation in which hydroquinone is replaced by thiamidol.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Criteria
Inclusion Criteria:- SIGNED WRITTEN CONSENT 1) Melasma clinically diagnosed
Exclusion Criteria:
1. Pregnant woman
2. Other pigmentary disorder affecting the face
3. Use of systemic or topical steroids or retinoids, use of topical depigmenting agents
or depigmenting procedure in the month before the inclusion